Abstract: Provided herein are formulations and methods of using a TLR-7 agonist for the treatment of hepatitis B virus infection.

Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Abstract: The present invention related to a method of manufacturing of a contamination control sheet, the method comprising the steps of: passing a web of support material from a supply roller to a coating station, and applying a coating of polymeric material to one surface of the support material; passing the coated support material through an oven to cure the polymeric material; and passing the coated support material around a cooling roller to a take up roller; characterised in that a nip roller is provided adjacent to the cooling roller so that the coated surface of the support material is pressed onto the cooling roller by the nip roller, and further characterised in that the cooling roller has a surface roughness of 0.2 to 1 Ra.

Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.

Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.

Abstract: Provided herein are formulations and methods of using a TLR-7 agonist for the treatment of hepatitis B virus infection.

Abstract: The present invention related to a method of manufacturing of a contamination control sheet, the method comprising the steps of: passing a web of support material from a supply roller to a coating station, and applying a coating of polymeric material to one surface of the support material; passing the coated support material through an oven to cure the polymeric material; and passing the coated support material around a cooling roller to a take up roller; characterised in that a nip roller is provided adjacent to the cooling roller so that the coated surface of the support material is pressed onto the cooling roller by the nip roller, and further characterised in that the cooling roller has a surface roughness of 0.2 to 1 Ra.

Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Abstract: A contamination control mat 10 comprising a support layer 16 which is coated on a top surface with a polymeric contamination control layer 17, wherein the support layer 16 comprises a glass fiber reinforced polymer that is printed on a top surface, the polymeric contamination control layer 17 is transparent or translucent, and the printed surface is visible through the polymeric contamination control layer. This provides a thin yet rigid and stable mat 10 that can also display printed information that is protected from damage. The mat 10 is primarily used to meet contamination control needs.

Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.

Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.

Abstract: A contamination control mat 10 comprising a support layer 16 which is coated on a top surface with a polymeric contamination control layer 17, wherein the support layer 16 comprises a glass fibre reinforced polymer that is printed on a top surface, the polymeric contamination control layer 17 is transparent or translucent, and the printed surface is visible through the polymeric contamination control layer. This provides a thin yet rigid and stable mat 10 that can also display printed information that is protected from damage. The mat 10 is primarily used to meet contamination control needs.

Abstract: The present disclosure relates to pharmaceutical compositions containing cenicriviroc or a salt thereof and optionally one or more additional pharmaceutically active agent, methods for the preparation thereof, and their use in the treatment of diseases or conditions, particularly viruses such as Human Immunodeficiency Virus (HIV).

Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.

Abstract: A method of producing 6-amino-cyclopenta[g]quinazolines, in enantiomerically enriched form, is provided. In particular, the method may be applicable to the synthesis of N—{N-{4-[N-((6S)-2 -hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2 -ynyl)amino]benzoyl}-L-?-glutamyl}-D-glutamic acid (ONX-0801).

Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.

Abstract: The present invention relates to the use of a high intensity, in-line rotor-stator apparatus to produce fine particles via antisolvent, reactive, salting out or rapid cooling precipitation and crystallization.

Abstract: The present invention relates to the use of a high intensity, in-line rotor-stator apparatus to produce fine particles via antisolvent, reactive, salting out or rapid cooling precipitation and crystallization.